Affimed (AFMD) Misses Q2 EPS by 1c; CMO Marschner to Resign
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Affimed (NASDAQ: AFMD) reported Q2 EPS of (EUR0.24), EUR0.01 worse than the analyst estimate of (EUR0.23).
Affimed announced that the Company’s Chief Medical Officer, Dr. Jens-Peter Marschner, has decided to step down as CMO. Since joining the Company in 2013, Dr. Marschner has expanded Affimed’s AFM13 and AFM11 clinical programs. Dr. Anne Kerber, Affimed’s Senior Medical Director, will assume the responsibility of leading the clinical team on an interim basis. Dr. Kerber, a board certified hematologist/oncologist, joined Affimed in January 2016 from Merck Serono where she oversaw the clinical development of several compounds. Dr. Marschner will continue to support Affimed as a consultant during the transition period. “Jens-Peter has been a highly valuable member of the management team. Under his leadership Affimed became a clinical development company. Jens-Peter built Affimed’s clinical team, developed an excellent clinical network, formed a distinguished SAB and initiated multiple new clinical trials for AFM11 and AFM13, including our combination therapy with Keytruda.
For earnings history and earnings-related data on Affimed (AFMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Under Armour (UA) Tops Q3 EPS by 4c; Reaffirms FY16 Outlook
- Sprint Corp. (S) Reports Q2 Loss of $0.04/Share
- Ryder System (R) Misses Q3 EPS by 1c; Cuts FY16 EPS Outlook